Composition

Glifomet Tablet: Each film coated tablet contains Empagliflozin INN 5 mg and Metformin Hydrochloride BP 500 mg.

Indication

Glifomet is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type

2 diabetes mellitus when treatment with both Empagliflozin and Metformin Hydrochloride is

inappropriate. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2

diabetes mellitus and established cardiovascular disease

Dose & Administration

• The starting dose of Glifomet should be based on the patient's current regimen.

• Take twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to Metformin Hydrochloride.

• The maximum recommended dose is 12.5 mg empagliflozin /1 000 mg metformin hydrochloride twice daily.

• Assess renal function before initiating Glifomet. Do not initiate or continue Glifomet if creatinine levels are greater than or equal to 1.5 mg /dL for males or 1.4 mg /dL for females or if eGFR is below 45 mL /min II.73 m2 or as directed by the physician.

Glix™ 80 Tablet: Each Tablet contains Gliclazide BP 80 mg.

Glix™ 30 MR Tablet: Each modified release tablet contains Gliclazide BP 30 mg.

Glix™ 60 MR Tablet: Each modified release tablet contains Gliclazide BP 60 mg.

Indicated for the treatment of Type-2 Diabetes.

Glix™ 80 Tablet: Initially 40-80 mg daily, adjusted according to response, increased if necessary up to 160 mg once daily. Dose to be taken with breakfast, dosage higher than 160 mg to be given in divided doses; maximum 320 mg per day.

Glix™ MR Tablet: Initially 30 mg daily, dose to be taken with breakfast, adjustdose according to response every 4 weeks (after 2 weeks if no decrease in blood glucose); maximum 120 mg per day. Or as directed by the physician.